Bayer’s Nubeqa improves survival in prostate cancer trial

FRANKFURT (Reuters) – Bayer says a combination therapy that includes its drug Nubeqa has been shown to prolong the lives of men with metastatic prostate cancer in a clinical study.

The German company said the drug, also known as darolutamide, improved overall survival when combined with standard care compared with standard care alone, which was the primary goal of the trial, the company said. German company said in a statement on Friday.

Details of the trial to be presented at a medical conference have not been disclosed, it added.

(Reporting by Ludwig Burger; Editing by Paul Carrel)

https://whbl.com/2021/12/03/bayers-nubeqa-drug-improves-survival-in-prostate-cancer-trial/ Bayer’s Nubeqa improves survival in prostate cancer trial


USTimeToday is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@ustimetoday.com. The content will be deleted within 24 hours.

Related Articles

Back to top button